Addex Therapeutics' Phase 2 epilepsy drug, ADX71149, failed to meet primary endpoint in a mid-stage study.

Addex Therapeutics' Phase 2 epilepsy drug, ADX71149 (JNJ-40411813), failed to meet its primary endpoint in a mid-stage study involving patients with focal onset seizures. The drug, co-developed with Johnson & Johnson's Janssen Pharmaceuticals, was well-tolerated but did not achieve statistical significance. Addex's stock price plummeted by 50.4% following the announcement.